Generated by AI
Inventiva S.A. American Depositary Receipt represents Inventiva S.A., a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical need. The company’s current research and development activities center on treatments for metabolic, fibrotic, inflammatory, and rare diseases, with a pipeline that includes programs in liver disease, oncology, fibrosis, and mucopolysaccharidoses. Inventiva S.A. operates as a biotechnology company with international clinical development activity, combining in-house discovery capabilities with late-stage and earlier-stage therapeutic programs. As an American Depositary Receipt, it provides U.S. market access to the company’s ordinary shares and reflects its role as a cross-border biotech issuer with exposure to specialty drug development and clinical research.
Website50 rue de Dijon
Daix, 21121
France
The latest articles about IVA.
Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.
Summary of Nov 3's posts. Generated by AI.
Summary of Oct 14's posts. Generated by AI.
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of diseaseAnalysis of plasma cell-free DNA (cfDNA) identified coordinated epigeneti
No summary yet.
Summary of Nov 3's posts. Generated by AI.
Investors talking about IVA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.